Liminatus Pharma, Inc. Class A Common Stock (LIMN) vs Soligenix, Inc. (SNGX)
A side-by-side comparison of Liminatus Pharma, Inc. Class A Common Stock and Soligenix, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
LIMN
Liminatus Pharma, Inc. Class A Common Stock
$3.83HealthcareDelayed quote: Oct 6, 2026, 1:18 PM EDT
SNGX
Soligenix, Inc.
$0.36HealthcareDelayed quote: Oct 6, 2026, 1:14 PM EDT
Total return — LIMN vs SNGX
growth of $100 · dividends reinvested · last 1yLIMN -98.4% (-98.4%/yr)SNGX -82.6% (-82.6%/yr)SNGX compounded faster over this window
Log scale — wide-divergence pair
LIMN SNGX
LIMN vs SNGX: by the numbers
- •SNGX is the larger company ($5M vs $5M market cap).
Metrics side by side
Valuation
| Metric | LIMN | SNGX |
|---|---|---|
| P/B ratio | 17.11 | 0.81 |
Profitability
| Metric | LIMN | SNGX |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -4165.92% | -154.08% |
| ROIC | -225.12% | -161.69% |
Growth (annualized)
| Metric | LIMN | SNGX |
|---|---|---|
| Total return CAGR (5Y) | N/A | -72.72% |
Go deeper
Dig into the metrics
Liminatus Pharma, Inc. Class A Common Stock ROESoligenix ROELiminatus Pharma, Inc. Class A Common Stock operating marginSoligenix operating marginLiminatus Pharma, Inc. Class A Common Stock revenue growthSoligenix revenue growthLiminatus Pharma, Inc. Class A Common Stock free cash flowSoligenix free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.